IL93610A0 - Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them - Google Patents

Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them

Info

Publication number
IL93610A0
IL93610A0 IL93610A IL9361090A IL93610A0 IL 93610 A0 IL93610 A0 IL 93610A0 IL 93610 A IL93610 A IL 93610A IL 9361090 A IL9361090 A IL 9361090A IL 93610 A0 IL93610 A0 IL 93610A0
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
tetrahydroquinoline derivatives
tetrahydroquinoline
Prior art date
Application number
IL93610A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898905334A external-priority patent/GB8905334D0/en
Priority claimed from GB898926431A external-priority patent/GB8926431D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL93610A0 publication Critical patent/IL93610A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL93610A 1989-03-08 1990-03-02 Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them IL93610A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898905334A GB8905334D0 (en) 1989-03-08 1989-03-08 Therapeutic agents
GB898926431A GB8926431D0 (en) 1989-11-22 1989-11-22 Therapeutic agents

Publications (1)

Publication Number Publication Date
IL93610A0 true IL93610A0 (en) 1990-12-23

Family

ID=26295073

Family Applications (1)

Application Number Title Priority Date Filing Date
IL93610A IL93610A0 (en) 1989-03-08 1990-03-02 Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them

Country Status (11)

Country Link
EP (1) EP0386839B1 (xx)
JP (1) JPH0334969A (xx)
KR (1) KR900014321A (xx)
AT (1) ATE147732T1 (xx)
AU (1) AU5114490A (xx)
CA (1) CA2011686A1 (xx)
DE (1) DE69029668T2 (xx)
FI (1) FI901148A0 (xx)
IL (1) IL93610A0 (xx)
NO (1) NO901082L (xx)
PT (1) PT93362A (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268378A (en) * 1990-05-31 1993-12-07 Merck Sharp & Dohme, Limited Dioxo-tetrahydroquinoline derivatives
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5606063A (en) * 1991-02-27 1997-02-25 Merrell Pharmaceuticals Inc. NMDA antagonists
ES2089511T3 (es) * 1991-02-27 1996-10-01 Merrell Pharma Inc Dihidroquinolina antagonistas de nmda.
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
FR2683818B1 (fr) * 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
WO1997012870A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
DE19705133A1 (de) * 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
EP1607389A1 (en) * 1999-09-10 2005-12-21 Pfizer Products Inc. 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
WO2002046185A1 (fr) * 2000-12-07 2002-06-13 Japan Science And Technology Corporation Intermediaires de synthese de composes de vinblastine et leur procede de synthese
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
EP2527339A1 (en) * 2004-11-24 2012-11-28 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23848A (en) * 1985-05-24 1989-11-23 Ciba Geigy Ag Certain phosphonic acids and derivatives
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DE69029668D1 (de) 1997-02-27
EP0386839B1 (en) 1997-01-15
NO901082D0 (no) 1990-03-07
NO901082L (no) 1990-09-10
EP0386839A3 (en) 1991-10-23
DE69029668T2 (de) 1997-08-07
CA2011686A1 (en) 1990-09-08
JPH0334969A (ja) 1991-02-14
PT93362A (pt) 1990-11-07
EP0386839A2 (en) 1990-09-12
ATE147732T1 (de) 1997-02-15
FI901148A0 (fi) 1990-03-07
AU5114490A (en) 1990-09-13
KR900014321A (ko) 1990-10-23

Similar Documents

Publication Publication Date Title
IL93610A0 (en) Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
NZ233495A (en) Heterocyclic n-oxide derivatives of substituted benzo(5,6)cycloheptapyridines and pharmaceutical compositions thereof
NZ222347A (en) Benzo(5,6)cycloheptapyridines and pharmaceutical compositions
IL95124A0 (en) Pharmaceutical compositions containing spirocyclic compounds,certain such novel compounds and their preparation
NZ224143A (en) Leukotriene antagonists, process for their preparation, and pharmaceutical compositions
IL69311A (en) 2-substituted 4-amino-6,7-dimethoxyquinoline derivatives and pharmaceutical compositions containing them
NO178398C (no) Piperidin derivater og farmasöytisk formulering
IL106990A0 (en) 7-isoindolinyl-quinoline derivatives and 7-isoindolinyl-naphthyridone derivatives,their preparation and pharmaceutical compositions containing them
NZ222030A (en) Substituted imidazo-(5,4-g (3,1 benzoxaminone derivatives and pharmaceutical compositions
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
IL93598A0 (en) (3-(c16-c18)-alkanesulphinyl-and-sulphonyl-2-methoxy-methylpropyl)-(2-trimethyl-ammoniumethyl)phosphates,processes for the preparation thereof and pharmaceutical compositions containing them
NZ219386A (en) Naphtho(1,2-b)-1,4-thiazepinone derivatives and pharmaceutical compositions
IL98863A0 (en) Carbostyril derivatives,their preparation and pharmaceutical compositions containing them
IL103980A0 (en) Substituted phthalides and heterocyclic phthalides,their preparation and pharmaceutical compositions containing them
EP0499414A3 (en) Pyridine derivatives as angiotensin ii antagonists, processes for their preparation and pharmaceutical compositions containing them
EP0441036A3 (en) Quinoline derivatives, processes for their preparation, intermediates, and pharmaceutical compositions containing these derivatives
NZ234369A (en) 6-(naphthalenylethyl)-4-hydroxy-pyran-2-one derivatives and the 3,5-dihydroxyheptanoates; pharmaceutical compositions
NZ227235A (en) Substituted 1,5-benzothiazepin-4-one derivatives and pharmaceutical compositions
IL88617A0 (en) Quinoline derivatives,the preparation thereof and pharmaceutical compositions containing them
IL101456A0 (en) Indole and dihydroquinoline derivatives,and pharmaceutical compositions containing the same
IL82099A0 (en) Substituted 1,3,5-triazine derivatives,processes for their preparation,and pharmaceutical compositions containing them
FI942675A0 (fi) Uudet substituoidut oksatsinoisokinoliinijohdannaiset, niitä sisältävät farmaseuttiset koostumukset sekä menetelmä niiden valmistamiseksi
DE69005241D1 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen.
IL95408A0 (en) Substituted heterocyclic fivemembered ring derivatives,their preparation and pharmaceutical compositions containing them
IL53700A (en) 6,7-dimethoxy(or diethoxy)-1,2,3,4-tetrahydroisoquinoline-1-acetamide derivatives,their preparation and pharmaceutical compositions containing them